Theranostic porphyrin dyad nanoparticles for magnetic resonance imaging guided photodynamic therapy
Source abstract
Abstract
Photodynamic therapy (PDT) is a site-specific treatment of cancer involving the administration of a photosensitizer (PS) followed by the local light activation. Besides efficient PSs, image guidance is essential for precise and safe light delivery to the targeting site, thus improving the therapeutic effectiveness. Herein, we report the fabrication of theranostic porphyrin dyad nanoparticles (TPD NPs) for magnetic resonance imaging (MRI)-guided PDT cancer therapy, where the inner metal free porphyrin functions as a photosensitizer for PDT while the outer Mn-porphyrin serve as an MRI contrast agent. Covalent attachment of porphyrins to TPD NPs avoids premature release during systemic circulation. In addition, TPD NPs (~60 nm) could passively accumulate in tumors and be avidly taken up by tumor cells. The PDT and MRI capabilities of TPD NPs can be conveniently modulated by varying the molar ratio of metal free porphyrin/Mn-porphyrin. At the optimal molar ratio of 40.1%, the total drug loading content is up to 49.8%, 31.3% for metal free porphyrin and 18.5% for Mn-porphyrin. The laser light ablated the tumor completely within 7 days in the presence of TPD NPs and the tumor growth inhibition was 100%. The relaxivities were determined to be 20.58 s(-1) mm(-1) for TPD NPs, about four times as much as that of Mn-porphyrin (5.16 s(-1) mm(-1)). After 24 h intravenous injection of TPD NPs, MRI images showed that the whole tumor area remained much brighter than surrounding healthy tissue, allowing to guide the laser light to the desired tumor site for photodynamic ablation.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Porphyrin and Phthalocyanine Chemistry
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (57)
Show source-provided references
1. Photodynamic therapeutics: basic principles and clinical applications10.1016/S1359-6446(99)01412-9 ↗
2. Photodynamic therapy for cancer10.1038/nrc1071 ↗
3. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization10.1021/cr900300p ↗
4. Photodynamic therapy of cancer: an update10.3322/caac.20114 ↗
5. Photodynamic therapy10.1093/jnci/90.12.889 ↗
6. Phospholipid-functionalized mesoporous silica nanocarriers for selective photodynamic therapy of cancer10.1016/j.biomaterials.2013.06.001 ↗
7. Mechanisms of photosensitized oxidation10.1126/science.162.3857.963 ↗
8. Photosensitizer-antibody conjugates for detection and therapy of cancer10.1016/j.addr.2003.09.003 ↗
9. Liposomal delivery of photosensitising agents10.1517/17425247.2.3.477 ↗
10. Liposomes for photodynamic therapy10.1016/j.addr.2003.07.014 ↗
11. Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy10.1021/ja0343095 ↗
12. Organically modified silica nanoparticles with covalently incorporated photosensitizer for photodynamic therapy of cancer10.1021/nl0714637 ↗
13. The role of porphyrin chemistry in tumor imaging and photodynamic therapy10.1039/B915149B ↗
14. Photosensitizer-conjugated silica-coated gold nanoclusters for fluorescence imaging-guided photodynamic therapy10.1016/j.biomaterials.2013.02.063 ↗
15. Imaging-guided pH-sensitive photodynamic therapy using charge reversible upconversion nanoparticles under near-infrared light10.1002/adfm.201202992 ↗
16. Photosensitizer loaded nano-graphene for multimodality imaging guided tumor photodynamic therapy10.7150/thno.8070 ↗
17. Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI10.1038/nm940 ↗
18. MR imaging-guided interstitial photodynamic laser therapy for advanced head and neck tumors
19. Chlorophyll-a analogues conjugated with aminobenzyl-DTPA as potential bifunctional agents for magnetic resonance imaging and photodynamic therapy10.1021/bc049807x ↗
20. ALA and photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre phase III randomised controlled trial10.1007/s10103-007-0494-2 ↗
21. Fluorescence image-guided surgery and repetitive photodynamic therapy in brain metastatic malignant melanoma10.1016/j.pdpdt.2009.01.001 ↗
22. Hexylether derivative of pyropheophorbide-a (HPPH) on conjugating with 3gadolinium(III) aminobenzyldiethylenetriaminepentaacetic acid shows potential for in vivo tumor imaging (MR, Fluorescence) and photodynamic therapy10.1021/bc9005317 ↗
23. Photosensitizer-conjugated magnetic nanoparticles for in vivo simultaneous magnetofluorescent imaging and targeting therapy10.1016/j.biomaterials.2011.01.032 ↗
24. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging10.1002/jmri.20793 ↗
25. New MR techniques for the detection of liver metastases10.1102/1470-7330.2006.0007 ↗
26. Small molecular gadolinium(III) complexes as MRI contrast agents for diagnostic imaging10.1016/j.ccr.2007.04.018 ↗
27. Magnetic resonance imaging for ischemic heart disease10.1002/jmri.20976 ↗
28. Bioresponsive, cell-penetrating, and multimeric MR contrast agents10.1021/ar800245h ↗
29. Gadolinium-based contrast agents and NSF: evidence from animal experience10.1002/jmri.21971 ↗
30. Nephrogenic systemic fibrosis and its impact on abdominal imaging10.1148/rg.296095517 ↗
31. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update10.1016/j.rcl.2009.06.006 ↗
32. A highly effective, nontoxic T1 MR contrast agent based on ultrasmall PEGylated iron oxide nanoparticles10.1021/nl902715v ↗
33. Investigation of in vivo targeting kinetics of αvβ3-specific superparamagnetic nanoprobes by high temporal resolution-MRI10.7150/thno/v01p0263 ↗
34. Mesoporous silica-coated hollow manganese oxide nanoparticles as positive T1 contrast agents for labeling and MRI tracking of adipose-derived mesenchymal stem cells10.1021/ja1084095 ↗
35. Correlation of relaxivity with coordination number in six-, seven-, and eight-coordinate Mn(II) complexes of pendant-arm cyclen derivatives10.1021/ic8003068 ↗
36. Synthesis and in vitro and in vivo evaluation of manganese(III) porphyrin–dextran as a novel MRI contrast agent10.1016/j.bmcl.2009.10.003 ↗
37. In vivo imaging with a cell-permeable porphyrin-based MRI contrast agent10.1016/j.chembiol.2010.05.009 ↗
38. Water-soluble porphyrins as a dual-function molecular imaging platform for MRI and fluorescence zinc sensing10.1073/pnas.0702393104 ↗
39. Revisiting an old friend: manganese-based MRI contrast agents10.1002/wnan.116 ↗
40. Paramagnetic metalloporphyrins as potential contrast agents in NMR imaging10.1016/0014-5793(84)80208-2 ↗
41. The anomalous relaxivity of Mn3+(TPPS4)10.1002/mrm.1910040306 ↗
42. Proton relaxation enhancement by manganese(III)TPPS4 in a model tumor system10.1016/0730-725X(87)90044-0 ↗
43. Tissue distribution and stability of metalloporphyrin MRI contrast agents10.1002/mrm.1910040104 ↗
44. Contrast-enhanced MRI with new biodegradable macromolecular Gd(III) complexes in tumor-bearing mice10.1002/mrm.20402 ↗
45. Conjugation of porphyrin to nanohybrid cerasomes for photodynamic diagnosis and therapy of cancer10.1002/anie.201103557 ↗
46. Covalent attachment of Mn-porphyrin onto doxorubicin-loaded poly(lactic acid) nanoparticles for potential magnetic resonance imaging and pH-sensitive drug delivery10.1016/j.actbio.2013.08.018 ↗
47. Gd3+-functionalized near-infrared quantum dots for in vivo dual modal (fluorescence/magnetic resonance) imaging10.1039/b812302k ↗
48. LeCours · J Am Chem Soc · 1996 · 118 · 1185410.1021/ja962403y ↗
49. Push-pull arylethynyl porphyrins: new chromophores that exhibit large molecular first-order hyperpolarizabilities10.1021/ja953610l ↗
50. LeCours · J Am Chem Soc · 1997 · 119 · 1257810.1021/ja964436j ↗
51. Model systems for fluorescence and singlet oxygen quenching by metalloporphyrins10.1002/cmdc.200600244 ↗
52. Silica-coated manganese oxide nanoparticles as a platform for targeted magnetic resonance and fluorescence imaging of cancer cells10.1002/adfm.200902445 ↗
53. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents10.1039/b510982p ↗
54. Synthesis of multimeric MR contrast agents for cellular imaging10.1021/ja0777990 ↗
55. PARACEST agents: modulating MRI contrast via water proton exchange10.1021/ar020228m ↗
56. Mesoporous silica nanospheres as highly efficient MRI contrast agents10.1021/ja710193c ↗
57. Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets10.1021/ja801482d ↗